Hey, S. P. et al.,
“Challenges and Opportunities for Biomarker Validation,” Journal of Law, Medicine & Ethics 47, no.
3 (
2019):
357-
361;
Shrager, J.,
Shapiro, M., and
Hoos, W., “Is Cancer Solvable? Towards Efficient and Ethical Biomedical Science,”
Journal of Law, Medicine & Ethics 47, no. 3 (2019): 369-373; S.P. Hey et al., Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence,
Journal of Law, Medicine & Ethics 47, no. 3 (2019): 381-387; L.M. McShane, Biomarker Validation: Context and Complexities,
Journal of Law, Medicine & Ethics 47, no. 3 (2019): 388-392; A.D. Zhang and J.S. Ross, Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation,
Journal of Law, Medicine & Ethics 47, no. 3 (2019): 393-395; A.D. Stern, Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures,
Journal of Law, Medicine & Ethics 47, no. 3 (2019): 396-397.
CrossRefGoogle Scholar